Oncotarget.net features press releases on the latest oncology research, as well as interviews from the distinguished network of authors who continue to publish their research with Oncotarget.

Tag: Mikhail Blagosklonny

Figure 2: Preemptive combinations. (A) EGFR-Mutant-Driven NSCLC. See text. (B) METex14-Driven NSCLC. See text.

Oncotarget

“From Osimertinib to Preemptive Combinations” by Dr. Blagosklonny

March 19, 2024

“Here I will re-introduce the notion of preemptive combinations (PC) of targeted drugs.” BUFFALO, NY- March 19, 2024 – A new research perspective was published by Mikhail V. Blagosklonny M.D.,… read more

PRESS RELEASE: On January 3, 2024, Mikhail V. Blagosklonny M.D., Ph.D., published a new brief report in Oncoscience (Volume 11), entitled, “My battle with cancer. Part 1.”

Oncotarget

Dr. Blagosklonny’s Battle With Cancer (Part 1)

January 22, 2024

“Diagnosed with numerous metastases of lung cancer in my brain in January 2023, I felt compelled to accomplish a mission.” BUFFALO, NY- January 22, 2024 – On January 3, 2024,… read more

Oncotarget

Going Beyond Open-Access Publishing

March 6, 2020

The field of academic research is growing at a very fast pace, with open-access journals pioneering a new field of freely available research. This type of free and accessible published… read more